3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
16
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Solid Tumors Refractory to Standard Therapy
1
Solid Tumors
1
Solid Tumor, Adult
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Kidney Neoplasms
1
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Interventions
Temozolomide
69
Radiotherapy
30
Bevacizumab
24
Carboplatin
13
pembrolizumab
12
Radiation
11
Carmustine
8
Irinotecan
7
temsirolimus
6
Surgical Procedures, Operative
6
Radiosurgery
6
Erlotinib Hydrochloride
6
atezolizumab
5
Vorinostat
5
Sirolimus
5
Radiotherapy, Intensity-Modulated
5
Nivolumab
5
Lomustine
5
Everolimus
5
fludarabine
4
Radiotherapy, Conformal
4
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Aminolevulinic Acid
4
tipifarnib
3
Sorafenib
3
Paclitaxel
3
IL13-PE38
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Gemcitabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Glioblastoma
×
palbociclib
×
Clear all
NCT03158389
2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2
Completed
228 enrolled